Skip to content
NJ News HubNewsHub

Health

Merck wins FDA approval for oral LDL cholesterol drug

Source: NJBiz · Jul 17, 2026, 7:58 AM

AI-assisted briefing from the publisher’s public headline and excerpt — not original reporting. How we write briefings

Merck wins FDA approval for oral LDL cholesterol drug news image

Merck has received FDA approval for Lipfendra, a groundbreaking oral PCSK9 inhibitor designed to help adults manage high LDL cholesterol and hypercholesterolemia.

This approval marks a significant milestone in cholesterol management therapy, offering patients an oral alternative to existing treatments.

The development represents an important advancement for the pharmaceutical company and provides new treatment options for patients dealing with elevated cholesterol levels.

Key points

  • Merck's Lipfendra is the first oral PCSK9 inhibitor approved by the FDA for LDL cholesterol management
  • The drug targets adults with high LDL cholesterol and hypercholesterolemia
  • This approval represents a significant advancement in oral cholesterol treatment options
  • Lipfendra offers an alternative to existing cholesterol management therapies

FAQ

What is Lipfendra and what does it treat?
Lipfendra is an oral PCSK9 inhibitor approved by the FDA for treating adults with high LDL cholesterol and hypercholesterolemia. It represents a new class of oral medications for cholesterol management.
Why is this FDA approval significant for patients?
This is the first oral PCSK9 inhibitor approved by the FDA, providing patients with a convenient oral alternative to existing cholesterol treatments, which may improve treatment adherence and patient outcomes.

Briefing prepared for NJ News Hub. Verify details on the original story. See our editorial policy.

Related